| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A computer-assisted cognitive test battery for aged monkeys
|
Buccafusco, Jerry J.
|
|
2002
|
19 |
1-2 |
p. 179-185
|
artikel
|
| 2 |
AF150(S) and AF267B
|
Fisher, Abraham
|
|
2002
|
19 |
1-2 |
p. 145-153
|
artikel
|
| 3 |
Alzheimer’s disease drug discovery targeted to the APP mRNA 5′Untranslated region
|
Rogers, Jack T.
|
|
2002
|
19 |
1-2 |
p. 77-82
|
artikel
|
| 4 |
Alzheimer’s therapeutics
|
Massa, Stephen M.
|
|
2002
|
19 |
1-2 |
p. 107-111
|
artikel
|
| 5 |
Amyloid peptide toxicity and microtubule-stabilizing drugs
|
Michaelis, Mary L.
|
|
2002
|
19 |
1-2 |
p. 101-105
|
artikel
|
| 6 |
Brain-imaging surrogate markers for detection and prevention of age-related memory loss
|
Small, Gary W.
|
|
2002
|
19 |
1-2 |
p. 17-21
|
artikel
|
| 7 |
Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial
|
Grundman, Michael
|
|
2002
|
19 |
1-2 |
p. 23-27
|
artikel
|
| 8 |
Calpain inhibitors
|
Rosa, Gabriella Di
|
|
2002
|
19 |
1-2 |
p. 135-141
|
artikel
|
| 9 |
Continuing strategies for inhibiting alzheimer’s γ-secretase
|
Wolfe, Michael S.
|
|
2002
|
19 |
1-2 |
p. 83-87
|
artikel
|
| 10 |
CREB and the discovery of cognitive enhancers
|
Scott, Roderick
|
|
2002
|
19 |
1-2 |
p. 171-177
|
artikel
|
| 11 |
Development of a new treatment for alzheimer’s disease and parkinson’s disease using anti-aggregatory β-synuclein-derived peptides
|
Windisch, Manfred
|
|
2002
|
19 |
1-2 |
p. 63-69
|
artikel
|
| 12 |
Development of indole-3-propionic acid (OXIGON™) for alzheimer’s disease
|
Bendheim, Paul E.
|
|
2002
|
19 |
1-2 |
p. 213-217
|
artikel
|
| 13 |
Discovery of new chemical classes of synthetic ligands that suppress neuroinflammatory responses
|
Watterson, D. Martin
|
|
2002
|
19 |
1-2 |
p. 89-93
|
artikel
|
| 14 |
Effects of aerobic fitness training on human cortical function
|
Kramer, Arthur F.
|
|
2002
|
19 |
1-2 |
p. 227-231
|
artikel
|
| 15 |
Estrogen and cognitive functioning in men with mild cognitive impairment
|
Sherwin, Barbara B.
|
|
2002
|
19 |
1-2 |
p. 219-223
|
artikel
|
| 16 |
Genetic and environmental risk factors for alzheimer’s disease in israeli arabs
|
Bowirrat, Abdalla
|
|
2002
|
19 |
1-2 |
p. 239-245
|
artikel
|
| 17 |
Lipid rafts play an important role in Aβ biogenesis by regulating the β-secretase pathway
|
Tun, Han
|
|
2002
|
19 |
1-2 |
p. 31-35
|
artikel
|
| 18 |
Modulation of axonal regeneration in neurodegenerative disease
|
Strittmatter, Stephen M.
|
|
2002
|
19 |
1-2 |
p. 117-121
|
artikel
|
| 19 |
NAP accelerates the performance of normal rats in the water maze
|
Gozes, Illana
|
|
2002
|
19 |
1-2 |
p. 167-170
|
artikel
|
| 20 |
Natural product extracts that reduce accumulation of the alzheimer’s amyloid β peptide
|
Yager, Debra
|
|
2002
|
19 |
1-2 |
p. 129-133
|
artikel
|
| 21 |
Nerve growth factor gene therapy for alzheimer’s disease
|
Tuszynski, Mark H.
|
|
2002
|
19 |
1-2 |
p. 207
|
artikel
|
| 22 |
Novel glycosaminoglycan precursors as anti-amyloid agents part II
|
Kisilevsky, Robert
|
|
2002
|
19 |
1-2 |
p. 45-50
|
artikel
|
| 23 |
Novel tricyclic pyrone compounds prevent intracellular APP C99-induced cell death
|
Jin, Lee-Way
|
|
2002
|
19 |
1-2 |
p. 57-61
|
artikel
|
| 24 |
Ovariectomy of young mutant amyloid precursor protein transgenic mice leads to increased mortality
|
Levin-Allerhand, Justine A.
|
|
2002
|
19 |
1-2 |
p. 163-166
|
artikel
|
| 25 |
Per-6-substituted β-cyclodextrin libraries inhibit formation of β-amyloid-peptide (Aβ)-derived, soluble oligomers
|
Yu, Jiaxin
|
|
2002
|
19 |
1-2 |
p. 51-55
|
artikel
|
| 26 |
Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in alzheimer’s disease
|
Kung, Mei-Ping
|
|
2002
|
19 |
1-2 |
p. 7-10
|
artikel
|
| 27 |
Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine® CX516 in elderly participants with mild cognitive impairment
|
Johnson, Steven A.
|
|
2002
|
19 |
1-2 |
p. 197-200
|
artikel
|
| 28 |
Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated?
|
Larry Sparks, D.
|
|
2002
|
19 |
1-2 |
p. 209-212
|
artikel
|
| 29 |
Significance and mechanism of alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion
|
Iqbal, Khalid
|
|
2002
|
19 |
1-2 |
p. 95-99
|
artikel
|
| 30 |
Slowing the progression of cognitive decline in alzheimer’s disease using mifepristone
|
Belanoff, Joseph K.
|
|
2002
|
19 |
1-2 |
p. 201-206
|
artikel
|
| 31 |
Statin therapy for Alzheimer’s disease
|
Petanceska, Suzana S.
|
|
2002
|
19 |
1-2 |
p. 155-161
|
artikel
|
| 32 |
Strategies for drug discovery for cognitive aging and alzheimer’s disease
|
Fillit, Howard M.
|
|
2002
|
19 |
1-2 |
p. 1-3
|
artikel
|
| 33 |
Structure-based functional design of chemical ligands for AMPA-subtype glutamate receptors
|
Zeng, Lei
|
|
2002
|
19 |
1-2 |
p. 113-116
|
artikel
|
| 34 |
Synthesis and evaluation of 2-(3′-lodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in alzheimer’s disease
|
Wang, Yanming
|
|
2002
|
19 |
1-2 |
p. 11-16
|
artikel
|
| 35 |
The genetics of exceptional human longevity
|
Perls, Thomas
|
|
2002
|
19 |
1-2 |
p. 233-238
|
artikel
|
| 36 |
The role of the low-density lipoprotein receptor-related protein (LRP1) in alzheimer’s Aβ generation
|
Goto, Joy J.
|
|
2002
|
19 |
1-2 |
p. 37-41
|
artikel
|
| 37 |
The utility of muscarinic agonists in the treatment of alzheimer’s disease
|
Messer, William S.
|
|
2002
|
19 |
1-2 |
p. 187-193
|
artikel
|
| 38 |
Towards a high-affinity allosteric enhancer at muscarinic M1 receptors
|
Lazareno, Sebastian
|
|
2002
|
19 |
1-2 |
p. 123-127
|
artikel
|
| 39 |
Using peptide nucleic acids as gene-expression modifiers to reduce β-amyloid levels
|
McMahon, Beth M.
|
|
2002
|
19 |
1-2 |
p. 71-76
|
artikel
|
Tijdschrift beschrijving